CCWM
RYTM icon

Cassaday & Co Wealth Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Cassaday & Co Wealth Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.3K Hold
93
– – ﹤0.01% 865
2026
Q1 		$8.09K Buy
+93
New +$9.04K ﹤0.01% 904

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cassaday & Co Wealth Management's RYTM Position: Q2 2026 in Review

Cassaday & Co Wealth Management held its Rhythm Pharmaceuticals (RYTM) position steady in Q2 2026 at 93 shares worth $10.3K. The position accounts for ﹤0.01% of the portfolio, ranked #865.

Cassaday & Co Wealth Management first reported a position in RYTM in Q1 2026 and has held it in 2 quarters since. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Cassaday & Co Wealth Management held 93 shares of Rhythm Pharmaceuticals worth $10.3K as of Q2 2026.
  • Cassaday & Co Wealth Management left its Rhythm Pharmaceuticals share count unchanged in Q2 2026.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Cassaday & Co Wealth Management's portfolio in Q2 2026, its #865 holding.
  • Cassaday & Co Wealth Management first reported a position in Rhythm Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.